DMII Drugs Made In America Acquisition II Corp.
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.…
Industry Peers
Shell CompaniesKey Statistics
About Drugs Made In America Acquisition II (NASDAQ: DMII)
›
Drugs Made In America Acquisition II (NASDAQ: DMII) is listed on Nasdaq, where its shares trade in USD. It belongs to the Shell Companies industry, part of the Financial Services sector.
The shares were at 10.25 USD on 19 November 2026.
At a market capitalisation of 652.92M USD, it trades at 34.2 times trailing earnings. The median trailing P/E of its 4 largest Shell Companies peers is 33.5, so DMII is valued in line with them.
Drugs Made In America Acquisition II reports return on equity of 0.9% and an operating margin of 0.0%.
Its debt exceeds its cash by 275.03K USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.